Eli Lilly and Company CEO and leadership

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM.

I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors.

I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

As President of Lilly Research Labs and Senior Vice President of Science and Technology at Eli Lilly and Company, Dan is responsible for developing the Lilly pipeline of molecules and speeding innovative medicines to patients. He previously was the Senior Vice President, Clinical and Product Development at Lilly. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals, a company that Dan founded in 2004 and subsequently served as President and CEO. At Avid, Dan led the discovery, development, and FDA approval of Amyvid®, the first diagnostic agent for brain imaging of beta-amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline. He currently serves as chairman of Avid.Dan trained as a resident in pathology and completed a fellowship in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biophysics and biochemistry at Yale University. ---I am an Eli Lilly and Company Digital Media Spokesperson and discuss topics related to Lilly, Lilly business and the healthcare environment. We operate in a highly regulated environment and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these guidelines: http://e.lilly/community

Patrik Jonsson is a senior vice president of Eli Lilly and Company, and the president of Lilly Bio-Medicines.

Since joining Lilly in 1991 as a sales representative, Patrik has held a number of positions in sales, marketing and general management. He served as European marketing director for Zyprexa and the neuroscience customer group, as managing director of Sweden and later of Scandinavia (Sweden, Norway and Denmark), and as president and general manager of Eli Lilly Italia. In 2012, when Lilly announced a new structure for the company’s European business, Patrik assumed additional responsibilities for the countries in central and southeastern Europe. In 2014, he became president and general manager of Lilly Japan.

Patrik is a business graduate from Lund University, School of Economics and Management, in Sweden.

He is the past chair of the Japan-based executive committee of PhRMA, and served on the board of the American Chamber of Commerce in Japan.

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM.

I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors.

I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines